title: [Preoperative intravenous iron as a strategy for blood saving in surgery for hip fracture].
abstract: OBJECTIVE
  To determine whether administration of intravenous iron in a patient diagnosed with hip fracture reduces the need for blood transfusion.
  
  
  METHODS
  A retrospective observational case-control study was performed comparing a control group of 63 patients diagnosed with hip fracture with another group of 57 patients treated with parenteral iron. Demographic, clinical condition/clinical record and hematometric differences of the case-control patients were described. We analyzed the morbidity (post-surgical infection) and mortality rate. SPSS(®) was used for statistical studies.
  
  
  RESULTS
  Being statistically significant, after the administration of intravenous iron sucrose, the need of blood transfusion was reduced in the case group, as well as the quantity of concentrates required (1.37 vs 0.6). In the case group, there was a statistically significant decreasing trend in hospital mortality rate (case group: 0.8%/control group: 8.3%). It was not been proven the relation between the decrease in nosocomial infection and the administration of intravenous iron
  
  
  CONCLUSIONS
  The administration of intravenous iron sucrose in patients diagnosed with hip fracture before surgery could be effective blood saving measure in this type of trauma surgery. Furthermore, its use has been reliable without causing any side effects.
authors.affiliation: Servicio de Cirugía Ortopédica y Traumatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. Electronic address: nievesblanco@hotmail.es.
authors.forename: Nieves
authors.initials: N
authors.lastname: Blanco Rubio
authors.forename: María
authors.initials: M
authors.lastname: Llorens Eizaguerri
authors.forename: Belén
authors.initials: B
authors.lastname: Seral García
authors.forename: Pilar
authors.initials: P
authors.lastname: Burillo Fuertes
authors.forename: Miguel
authors.initials: M
authors.lastname: Ranera García
authors.forename: Jorge
authors.initials: J
authors.lastname: Albareda Albareda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016063:Blood Loss, Surgical; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D016022:Case-Control Studies; D003428:Cross Infection / Q000453:epidemiology / Q000517:prevention & control; D004341:Drug Evaluation; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D005265:Femoral Neck Fractures / Q000601:surgery; D005290:Ferric Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D011292:Premedication; D011300:Preoperative Care; D012189:Retrospective Studies; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D005290:Ferric Compounds; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid